gsk4527226
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 11, 2023 (NCT06079190)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Neurotensin receptor 3INHIBITOR
SORT1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07105709 | Phase 2 | Aug 14, 2025 | Alector Inc., GlaxoSmithKline |
| NCT06079190 | Phase 2 | Oct 11, 2023 | Alector Inc., GlaxoSmithKline |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alector Inc. | For profit | 2 | 0 | 1 | 2023 |
| GlaxoSmithKline | For profit | 2 | 2 | 1 | 2023 |
2 organizations
Page 1 / 1